Theriva shareholders approve 8.9x stock plan share increase and 25x authorized share increase.

Theriva Biologics, Inc.

Stockholders approved Amendment No. 2 to the 2020 Stock Incentive Plan, increasing the share reserve from 280,000 to 2,500,000 shares.
Non-employee director annual grant limit raised from 40,000 to 250,000 shares under the amended plan.
Certificate of Change filed to increase authorized common shares from 14,000,000 to 350,000,000, effective November 1, 2024.
All four director nominees elected; BDO USA, P.C. ratified as independent auditor for FY2024.
Shareholders also approved the adjournment proposal, but it was not needed as quorum was present.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Theriva Biologics, Inc.: increased authorized shares of common stock from 14,000,000 to 350,000,000 (effective 2024-11-01).

Change: charter amendment
Effective: 2024-11-01

Exact text from the filing

On November 1, 2024, the Company filed a Certificate of Change to its Articles of Incorporation with the Secretary of State of the State of Nevada (the “Certificate of Change”) that was effective on such date that increased the number of the Company’s authorized shares of common stock, $0.001 par value per share from 14,000,000 shares to $350,000,000 shares.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-113480

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.